Identify underlying allergy aetiology

Article

Search for common clues to complicating factors, including blephartis and dry eye

Aplethora of effective antihistamines does little to relieve ocular allergies when complicated by other concomitant factors, said Dr Michael B. Raizman, at the 29th annual Current Concepts in Ophthalmology conference held in association with the Wilmer Eye Institute.

"You would think allergy would be easy to treat," said Dr Raizman, associate professor of ophthalmology, Tufts University School of Medicine, Boston, Massachusetts, USA. "We have the best antihistamines in the world. They are incredibly effective, yet our patients still come in complaining. They've tried everything, and nothing is working. Why is that?"

Obvious allergic conjunctivitis

This condition is seasonal and caused by pollens in the air. Patients may complain that the overthecounter (OTC) eye drops they use no longer work, Dr Raizman said. The most common reason for this type of failure for allergy treatment is the presence of other conditions of the ocular surface.

"[More than] 75% of treatment failures are caused by either dry eye or blepharitis," he said.

"You must treat the allergy and the under­lying dry eye or blepharitis as well," Dr Raizman said. "Sometimes, many patients can have all three of these - to varying degrees."

The presence of dry eye may not always be obvious. In such cases, lissamine green staining and rose bengal staining are often useful.

"Try to think of all three together, and treat all of them," he said. "Patients may be describing what sound to you like allergies. You can treat their allergies all you want, but if their blepharitis is bothering them, they will view the allergy treatment as a failure."

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.